Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Gross Margin: 2017-2025

Historic Gross Margin for Autolus Therapeutics (AUTL) over the last 8 years, with Sep 2025 value amounting to -35.15%.

  • Autolus Therapeutics' Gross Margin fell 13515.00% to -35.15% in Q3 2025 from the same period last year, while for Sep 2025 it was -61.21%, marking a year-over-year decrease of 16121.00%. This contributed to the annual value of -12.52% for FY2024, which is 11252.00% down from last year.
  • According to the latest figures from Q3 2025, Autolus Therapeutics' Gross Margin is -35.15%, which was down 108.79% from -16.83% recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Gross Margin high stood at 100.00% for Q4 2021, and its period low was -39,165.52% during Q4 2024.
  • For the 3-year period, Autolus Therapeutics' Gross Margin averaged around -3,582.67%, with its median value being 13.24% (2023).
  • Its Gross Margin has fluctuated over the past 5 years, first spiked by 77,468bps in 2023, then tumbled by 3,926,552bps in 2024.
  • Autolus Therapeutics' Gross Margin (Quarterly) stood at 100.00% in 2021, then remained steady at 100.00% in 2022, then remained steady at 100.00% in 2023, then plummeted by 3,926,552bps to -39,165.52% in 2024, then crashed by 13,515bps to -35.15% in 2025.
  • Its last three reported values are -35.15% in Q3 2025, -16.83% for Q2 2025, and -99.86% during Q1 2025.